Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-25 vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA),Breakthrough pain in cancer patients (off-label),Anesthesia (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily metabolized via CYP3A4 to norfentanyl (major inactive metabolite) and other minor metabolites.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~80-85% bound to plasma proteins (mainly albumin, also alpha-1-acid glycoprotein)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
6-10 L/kg (large, indicating extensive tissue distribution; Vd 6.4 L/kg in adults)
4-6 L/kg; large Vd indicates extensive tissue distribution
Transdermal: ~92% absolute bioavailability (fentanyl absorbed through skin; compared to IV administration)
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For GFR 10-50 m L/min: start with 12 mcg/hour patch; for GFR <10 m L/min: avoid use due to accumulation of active metabolite; consider alternative therapy.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A or B: reduce starting dose by 50% (e.g., start with 12 mcg/hour); Child-Pugh Class C: avoid use or use with extreme caution and close monitoring.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For children aged 2-16 years: initial dose based on opioid tolerance; typical starting dose for opioid-naive: 25 mcg/hour transdermal patch every 72 hours is not recommended; use lower strength or immediate-release opioids; refer to institutional guidelines.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest available strength (12 mcg/hour) and titrate cautiously; monitor for respiratory depression and constipation; avoid in frail elderly if possible.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DURAGESIC. Ensure accuracy when prescribing, dispensing, and administering DURAGESIC. Dosage errors can result in accidental overdose or death. Concomitant use with CYP3A4 inhibitors, potent CYP3A4 inducers, or the cessation of CYP3A4 inducers can cause fatal respiratory depression. DURAGESIC is contraindicated in opioid-non-tolerant patients and in acute or postoperative pain.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Life-threatening respiratory depression,Accidental exposure to children,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Adrenal insufficiency,Hypotension and bradycardia,Severe hypotension,Risks in patients with gastrointestinal obstruction,Seizures in patients with seizure disorders,Life-threatening QT prolongation at high doses
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Opioid non-tolerant patients,Acute or short-term pain,Postoperative pain,Significant respiratory depression,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction,Known hypersensitivity to fentanyl or any component of the system
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they increase the risk of respiratory depression and sedation. No specific food interactions; however, grapefruit juice may theoretically increase fentanyl levels via CYP3A4 inhibition, but clinical significance is minimal. Advise patients to maintain consistent dietary habits.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid unless benefits outweigh risks.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fentanyl is excreted in breast milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure with maternal therapeutic doses, but risk of sedation/respiratory depression in infants. Use with caution; monitor infant for drowsiness and feeding difficulties.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No established dose changes; pharmacokinetics in pregnancy show increased clearance and volume of distribution. Individualize dosing based on pain severity and response; monitor for under- or overdosing. Titrate to effect with caution.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
DURAGESIC-25 delivers fentanyl at 25 mcg/h transdermally. The reservoir system may leak if cut, potentially causing fatal overdose. Apply to non-irritated, non-hairy skin on upper torso. Do not apply heat sources (heating pads, hot tubs) as they increase absorption rate. Onset of action is 12-24 hours; titrate no more frequently than every 3 days. Use only in opioid-tolerant patients due to risk of respiratory depression. Monitor for serotonin syndrome if co-administering serotonergic drugs.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply the patch to clean, dry, non-hairy skin on the upper body; change every 72 hours.,Do not cut, tear, or damage the patch; do not use if the pouch seal is broken.,Avoid exposing the patch area to direct heat sources such as heating pads, electric blankets, hot tubs, or prolonged sun exposure.,Keep patches out of reach of children and pets; dispose of used patches by folding adhesive sides together and flushing down the toilet.,Do not stop using this medication abruptly; withdrawal may occur.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-25 vs ABSTRAL, answered by our medical review team.
DURAGESIC-25 is a Opioid Analgesic that works by Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-25 and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-25 is: Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-25 and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-25 is classified as Category C. First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal s. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.